Anthony Tolcher
Medical Oncology · San Antonio, TXNPI 1184627663
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $88,440 of the $125,031 with a category attached, or 70.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.1%. 2025 is the largest year on record at $39,604, 2.0 times the $19,597 reported in 2019.
Across 311 payments — averaging $402.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$19K
- F. Hoffmann-la Roche AG$17K
- Merck Healthcare Kgaa$17K
- Jazz Pharmaceuticals Inc.$12K
- Boehringer Ingelheim International GmbH$10K
- Theratechnologies Inc.$9K
- plus $40K from 54 others
Across 3,911 payments — averaging $4034.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4.2M
- AbbVie$1.7M
- Daiichi Sankyo Inc.$1.4M
- Pfizer$1.2M
- Boehringer Ingelheim$1.2M
- Deciphera Pharmaceuticals Inc.$1.1M
- plus $5M from 20 others
What the payments were for
- Consulting fees$88,44071%
- Speaking & faculty fees$6,2605%
- Travel & lodging$22,51918%
- Food & beverage$7,2296%
- Education$5840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$125,031 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 105 | $1,513,816 |
| ErleadaApalutamide | 19 | $337,109 |
| LynparzaOlaparib | 17 | $210,039 |
| Abiraterone Acetate | 55 | $130,382 |
| EliquisApixaban | 20 | $9,720 |
| XareltoRivaroxaban | 11 | $6,419 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $951 |
| Levothyroxine Sodium | 31 | $328 |
| Prednisone | 70 | $254 |
| Hydrocortisone | 14 | $229 |
| Escitalopram Oxalate | 14 | $108 |
| Gabapentin | 11 | $107 |
| Sertraline Hcl | 17 | $50 |
| Lorazepam | 12 | $44 |
| EuthyroxLevothyroxine Sodium | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $408 | $1,513,816105 claims |
| Johnson & JohnsonErleada, Xarelto | $617 | $343,52830 claims |
| AstraZenecaLynparza | $2,504 | $210,03917 claims |
| PfizerEliquis | $18,903 | $9,72020 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $32 | $32831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 495 medical oncology providers in Texas.
Other medical oncology in San Antonio
- Vijay GunugantiSan Antonio$1.5M
- Virginia KaklamaniSan Antonio$787K
- John SarantopoulosSan Antonio$588K
- Sukeshi AroraSan Antonio$188K
- Zohra NooruddinSan Antonio$113K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.